14 results for "Andrea Rubbert-Roth"

Safety and Efficacy of Upadacitinib in Patients with Rheumatoid Arthritis Refractory to Biologic DMARDs: Results Through Week 216 from the SELECT-CHOICE Study

Andrea Rubbert-Roth; Koji Kato; Boulos Haraoui et al.

Rheumatology and Therapy, Vol. 11 No. 5 · 2024 · English · DOAJ Scopus

Abstract Introduction The safety and efficacy of upadacitinib 15 mg (UPA15) through week 216 was evaluated in patients with rheumatoid arthritis (RA) from the long-term extension (LTE) of the phase 3 SELECT-CHOICE study. Methods Patients with RA refractory to biologic disease-modifying…

Association between low hemoglobin, clinical measures, and patient-reported outcomes in patients with rheumatoid arthritis: results from post hoc analyses of three phase III trials of sarilumab

Andrea Rubbert-Roth; Daniel E. Furst; Stefano Fiore et al.

Arthritis Research & Therapy, Vol. 24 No. 1 · 2022 · English · DOAJ Scopus

Abstract Background Anemia is common in patients with rheumatoid arthritis (RA). Higher hemoglobin (Hb) levels may be associated with better clinical outcomes and patient-reported outcomes (PROs). To assess this hypothesis, we conducted two post hoc analyses in three sarilumab phase III studies…

Golimumab for the Treatment of Rheumatoid Arthritis: A Narrative Review of Pivotal Randomized Trials and Real-World Studies

Uta Kiltz; Yi-Ming Chen; Andrea Rubbert-Roth et al.

Rheumatology and Therapy, Vol. 13 No. 4 · 2026 · English · DOAJ Scopus

Abstract Rheumatoid arthritis (RA) is a chronic, inflammatory autoimmune disease characterized by progressive joint involvement. The disease is associated with reduced health-related quality of life, functional ability, work productivity, and daily activity, in addition to pain, fatigue, and…

Efficacy and safety of upadacitinib in patients with rheumatoid arthritis and inadequate response or intolerance to biological treatments: results through 5 years from the SELECT-BEYOND study

Roy Fleischmann; Stephen Hall; Bernard Combe et al.

RMD Open, Vol. 10 No. 3 · 2024 · English · DOAJ Scopus

Objective To evaluate the efficacy and safety of upadacitinib over 5 years among patients with rheumatoid arthritis (RA) in a long-term extension (LTE) of the SELECT-BEYOND phase 3 trial.Methods Patients refractory to ≥1 biological disease-modifying antirheumatic drug (DMARD) received upadacitinib…

Sleep improvement in patients with rheumatoid arthritis treated with upadacitinib in real-world practice: results from the SLEERA study

Thomas Hügle; Heino Prillwitz; Godehard Scholz et al.

Arthritis Research & Therapy, Vol. 28 No. 1 · 2026 · English · DOAJ Scopus

Abstract Background Sleep impairment is common in rheumatoid arthritis (RA) but has not been extensively studied with wearables and self-observation following treatment. This study investigates the impact of upadacitinib (UPA) on subjective (self-reported) and objective (actigraphy-based) sleep…

Safety Profile of Upadacitinib up to 5 Years in Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis: An Integrated Analysis of Clinical Trials

Gerd R. Burmester; Jayne Stigler; Andrea Rubbert-Roth et al.

Rheumatology and Therapy, Vol. 11 No. 3 · 2024 · English · DOAJ Scopus

Abstract Introduction This integrated analysis of the phase 2/3 and phase 3 SELECT trials describes the safety profile of upadacitinib, an oral Janus kinase inhibitor, for up to 5 years of exposure across psoriatic arthritis (PsA), ankylosing spondylitis (AS), and non-radiographic axial…

Malignancy in the Upadacitinib Clinical Trials for Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis

Andrea Rubbert-Roth; Adriana M. Kakehasi; Tsutomu Takeuchi et al.

Rheumatology and Therapy, Vol. 11 No. 1 · 2023 · English · DOAJ Scopus

Abstract Introduction This article aims to describe malignancies in patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), or non-radiographic axial spondyloarthritis (nr-axSpA) treated with upadacitinib (UPA) or active comparators. Methods This integrated…

Patient Disease Trajectories in Rheumatoid Arthritis Patients Treated with Baricitinib 4-mg in Four Phase 3 Clinical Studies

Peter C. Taylor; Yun-Fei Chen; Janet Pope et al.

Rheumatology and Therapy, Vol. 10 No. 2 · 2023 · English · DOAJ Scopus

Plain Language Summary Baricitinib is an oral agent widely approved for the treatment of moderately to severely active rheumatoid arthritis). Although baricitinib (and other agents) have demonstrated efficacy at the population level, treatment responses vary considerably between individual…

Early axial spondyloarthritis according to the ASAS consensus definition: characterisation of patients and effectiveness of a first TNF inhibitor in a large observational registry

Oliver Distler; Diego Kyburz; Adrian Ciurea et al.

RMD Open, Vol. 9 No. 4 · 2023 · English · DOAJ Scopus

Objective To characterise the population fulfilling the Assessment of SpondyloArthritis international Society (ASAS) consensus definition of early axial spondyloarthritis (axSpA) and to determine the effectiveness of a first tumour necrosis factor inhibitor (TNFi) in early versus established axSpA…

Postvaccination anti-S IgG levels predict anti-SARS-CoV-2 neutralising activity over 24 weeks in patients with RA

Johannes von Kempis; Andrea Rubbert-Roth; Burkhard Ludewig et al.

RMD Open, Vol. 8 No. 2 · 2022 · English · DOAJ Scopus

Objectives To correlate immune responses following a two-dose regimen of mRNA anti-SARS-CoV-2 vaccines in patients with rheumatoid arthritis (RA) to the development of a potent neutralising antiviral activity.Methods The RECOVER study was a prospective, monocentric study including patients with RA…

Identification of individuals at high risk of developing rheumatoid arthritis: a balanced random forest model in a cohort of 1544 first-degree relatives

Axel Finckh; Delphine S Courvoisier; Celine Lamacchia et al.

RMD Open, Vol. 11 No. 4 · 2025 · English · DOAJ Scopus

Objectives To identify in a genetically susceptible population individuals at higher risk of developing rheumatoid arthritis (RA) using a classification approach combining known epidemiological risk factors, serological biomarkers, genetics, clinical signs and symptoms.Methods We used data from the…

Type of mRNA COVID-19 vaccine and immunomodulatory treatment influence humoral immunogenicity in patients with inflammatory rheumatic diseases

Catherine E. Raptis; Christoph T. Berger; Adrian Ciurea et al.

Frontiers in Immunology, Vol. 13 · 2022 · English · DOAJ Scopus

Patients with inflammatory rheumatic diseases (IRD) are at increased risk for worse COVID-19 outcomes. Identifying whether mRNA vaccines differ in immunogenicity and examining the effects of immunomodulatory treatments may support COVID-19 vaccination strategies. We aimed to conduct a long-term…

Differences in treatment response between female and male psoriatic arthritis patients during IL-12/23 therapy with or without methotrexate: post hoc analysis of results from the randomised MUST trial

Frank Behrens; Jürgen Rech; Jürgen Braun et al.

RMD Open, Vol. 9 No. 4 · 2023 · English · DOAJ Scopus

Background The influence of sex on treatment outcomes during interleukin-12/23 therapy in patients with psoriatic arthritis (PsA) has not been explored.Objective To conduct exploratory post hoc analyses of sex-stratified data from the MUST trial, an investigator-initiated, multicentre, phase 3b…

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update

Josef S Smolen; Robert Landewé; Sytske Anne Bergstra et al.

Annals of the Rheumatic Diseases · 2022 · English · OpenAlex Scopus